Copyright
©The Author(s) 2024.
World J Diabetes. Jul 15, 2024; 15(7): 1398-1403
Published online Jul 15, 2024. doi: 10.4239/wjd.v15.i7.1398
Published online Jul 15, 2024. doi: 10.4239/wjd.v15.i7.1398
Figure 1 Toll-like receptor activation by binding of damage-associated molecular patterns or pathogen-associated molecular patterns results in nuclear translocation of nuclear factor-kappa B transcription factors.
According to the results of Wu et al[23], microRNA-630 reduces the renal Toll-like receptor 4 levels diabetic kidney disease in rats, attenuates the expression of pro-inflammatory cytokines tumor necrosis factor-α, interleukin (IL)-1β, and IL-6, and improves albuminuria and glycemia. DAMPs: Damage-associated molecular patterns; TLR: Toll-like receptor; NF-κB: Nuclear factor-kappa B.
- Citation: Donate-Correa J, González-Luis A, Díaz-Vera J, Hernandez-Fernaud JR. MicroRNA-630: A promising avenue for alleviating inflammation in diabetic kidney disease. World J Diabetes 2024; 15(7): 1398-1403
- URL: https://www.wjgnet.com/1948-9358/full/v15/i7/1398.htm
- DOI: https://dx.doi.org/10.4239/wjd.v15.i7.1398